Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
Conditions:  TNBC - Triple-Negative Breast Cancer;  Head and Neck Squamous Cell Carcinoma;  Squamous Cell Carcinoma of Anal Canal;  Uveal Melanoma;  Glioblastoma;  Colorectal Cancer;  Chordoma;  Squamous Cell Carcinoma of the Lung;  KRAS G12D;  KRAS G13D;  EGFR Amp lification;  Epithelial Ovarian Cancer;  Hepatocellular Carcinoma;  Anaplastic Thyroid Cancer;  Pancreas Cancer Interventions:  Drug: BCA101;  Drug: Pembrolizumab Sponsor:  Bicara Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chordoma | Melanoma | Research | Skin Cancer | Study